BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38083866)

  • 41. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
    Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
    Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.
    Shelton SN; Shawgo ME; Matthews SB; Lu Y; Donnelly AC; Szabla K; Tanol M; Vielhauer GA; Rajewski RA; Matts RL; Blagg BS; Robertson JD
    Mol Pharmacol; 2009 Dec; 76(6):1314-22. PubMed ID: 19741006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
    El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
    Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
    Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
    Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain.
    Terracciano S; Russo A; Chini MG; Vaccaro MC; Potenza M; Vassallo A; Riccio R; Bifulco G; Bruno I
    Sci Rep; 2018 Jan; 8(1):1709. PubMed ID: 29374167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
    Moses MA; Henry EC; Ricke WA; Gasiewicz TA
    Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
    Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
    Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD
    Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel matrinic acid derivatives bearing 2-anilinothiazole structure for non-small cell lung cancer treatment with improved Hsp90 targeting effect.
    Xu Y; Zeng P; Wang H; Han K; Qiu G; Wei Y; Chen R; Wang L; Liu X
    Drug Dev Res; 2022 Sep; 83(6):1434-1454. PubMed ID: 35841121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
    Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
    Le Bras G; Radanyi C; Peyrat JF; Brion JD; Alami M; Marsaud V; Stella B; Renoir JM
    J Med Chem; 2007 Nov; 50(24):6189-200. PubMed ID: 17979263
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
    Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
    Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
    Koay YC; Wahyudi H; McAlpine SR
    Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. C-Terminal HSP90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1α through the Oxygen-Dependent Degradation Pathway.
    Kataria N; Martinez CA; Kerr B; Zaiter SS; Morgan M; McAlpine SR; Cook KM
    Cell Physiol Biochem; 2019; 53(3):480-495. PubMed ID: 31486323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-NSCLC activity in vitro of Hsp90
    Li HJ; Wang QS; Han W; Zhou H; Li P; Zhou F; Qin W; Zhao D; Zhou X; He CX; Xing L; Li PQ; Jin X; Yu F; He JH; Cao HL
    J Struct Biol; 2021 Jun; 213(2):107710. PubMed ID: 33610655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.
    Matthews SB; Vielhauer GA; Manthe CA; Chaguturu VK; Szabla K; Matts RL; Donnelly AC; Blagg BS; Holzbeierlein JM
    Prostate; 2010 Jan; 70(1):27-36. PubMed ID: 19739131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma.
    Zajec Ž; Dernovšek J; Distel M; Gobec M; Tomašič T
    Bioorg Chem; 2023 Feb; 131():106311. PubMed ID: 36495678
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer.
    Park JM; Kim YJ; Park S; Park M; Farrand L; Nguyen CT; Ann J; Nam G; Park HJ; Lee J; Kim JY; Seo JH
    Mol Cancer; 2020 Nov; 19(1):161. PubMed ID: 33218356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.